Novel fluorescent broth microdilution method for fluconazole susceptibility testing of Candida albicans

Journal of Clinical Microbiology

Volumn 39, Issue 7, 2001, Pages 2708-2712

  Liao, R S ^a   Rennie, R P ^a   Talbot, J A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CULTURE MEDIUM; DILUTION; DRUG SENSITIVITY; FLUORESCENCE; FUNGUS CULTURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; FLUCONAZOLE; FLUORESCEINS; HUMANS; MICROBIAL SENSITIVITY TESTS;

CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; FUNGI;

EID: 0034951741     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.39.7.2708-2712.2001     Document Type: Article

References (29)

1. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis
2. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989
3. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990
4. National nosocomial infections surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System
5. International conference for the development of a consensus on the management and prevention of severe candidal infections
6. Antifungal agents and susceptibility tests
7. Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts
8. Development of a robust flow cytometric assay for determining numbers of viable bacteria
9. Candidemia in a Canadian tertiary care hospital from 1976 to 1996
10. Assessment of the effect of amphotericin B on the vitality of Candida albicans
11. The trailing endpoint phenotype in antifungal susceptibility testing is pH dependent
12. Laboratory evaluation of antifungal agents: A comparative study of five imidazole derivatives of clinical importance
13. Laboratory tests for the activity of imidazole and triazole antifungal agents in vitro
14. Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates
15. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
16. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870
17. Antifungal susceptibility testing: Current state of technology, limitations, and standardization
18. Fluorescence microscopy methods for yeast
19. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method
20. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing clinical isolates in a murine model of invasive candidiasis
21. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
22. Antifungal susceptibility testing
23. Current and emerging azole antifungal agents
24. Trends and sources of nosocomial fungaemia
25. Comparative evaluation of macrodilution and Alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates
26. Candida, Cryptococcus, and other yeasts of medical importance
27. Hospital-acquired candidemia. The attributable mortality and excess length of stay
28. Candidemia at selected Canadian sites: Results from the Fungal Disease Registry